论文部分内容阅读
目的:对比观察瑞舒伐他汀、辛伐他汀治疗高脂血症伴发冠心病(CHD)的临床疗效。方法:收集2014年2月-2016年3月我院接诊收治的128例高脂血症伴发CHD患者随机分为两组,每组各64例,两组均行常规药物治疗,对照组加用辛伐他汀,观察组加用瑞舒伐他汀,检测两组治疗前后血脂指标及炎症指标,观察不良反应情况。结果:观察组血脂指标(TC、TG、LDL-C、HDL-C)及炎症指标(hs-CRP)治疗后均得到明显改善,且显著优于对照组(P<0.05);两组不良反应发生率相近(6.3%vs4.7%)(P>0.05)。结论:瑞舒伐他汀对高脂血症伴发CHD的调脂消炎作用更加理想,而且安全性高,临床疗效优于辛伐他汀。
Objective: To compare the clinical efficacy of rosuvastatin and simvastatin in the treatment of coronary heart disease (CHD) with hyperlipidemia. Methods: A total of 128 patients with hyperlipidemia and CHD admitted to our hospital from February 2014 to March 2016 were randomly divided into two groups (64 cases in each group), and the two groups were treated with conventional drugs. The control group Plus simvastatin, observation group plus rosuvastatin, blood lipid and inflammation indicators were measured before and after treatment to observe the adverse reactions. Results: The levels of TC, TG, LDL-C, HDL-C and hs-CRP in the observation group were significantly improved after treatment and were significantly better than those in the control group (P <0.05). The two groups of adverse reactions The incidence was similar (6.3% vs 4.7%) (P> 0.05). Conclusion: Rosuvastatin is more ideal for lipid-lowering and anti-inflammatory effects of hypercholesterolemia associated with CHD, and its safety is better than that of simvastatin.